Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Obesity diminishes response to PD-1-based immunotherapies in renal cancer.

Autor: Boi SK; Graduate Biomedical Sciences, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Orlandella RM; Graduate Biomedical Sciences, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Gibson JT; Graduate Biomedical Sciences, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Turbitt WJ; Department of Nutrition Sciences, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Wald G; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Thomas L; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Buchta Rosean C; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Norris KE; Honors Undergraduate Research Program, School of Health Professions, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Bing M; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Bertrand L; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Gross BP; Interdisciplinary Program in Immunology, The University of Iowa, Iowa City, Iowa, USA., Makkouk A; Interdisciplinary Program in Immunology, The University of Iowa, Iowa City, Iowa, USA., Starenki D; HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA., Farag KI; Science and Technology Honors Program, College of Arts and Sciences, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Sorge RE; Department of Psychology, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Brown JA; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA.; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA., Gordetsky J; Departments of Pathology and Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Yasin H; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.; Department of Internal Medicine, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Garje R; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.; Genitourinary Oncology Program, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Nandagopal L; Division of Hematology and Oncology, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.; The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, USA., Weiner GJ; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.; Department of Internal Medicine, Division of General Medicine, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA., Lubaroff DM; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA.; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA., Arend RC; The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, USA.; Department of Obstetrics and Gynecology, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA., Li P; Department of Biostatistics, The University of Alabama at Birmingham School of Nursing, Birmingham, Alabama, USA., Zakharia Y; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.; Genitourinary Oncology Program, Division of Hematology, Oncology and Blood and Marrow Transplantation, The University of Iowa, Iowa City, Iowa, USA., Yang E; The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, USA.; Department of Radiation Oncology, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA., Salem AK; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.; Division of Pharmaceutics and Translational Therapeutics, University of Iowa College of Pharmacy, Iowa City, Iowa, USA., Nepple K; Department of Urology, University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA.; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA., Marquez-Lago TT; Department of Genetics, The University of Alabama at Birmingham, Birmingham, Alabama, USA.; Department of Cell, Developmental and Integrative Biology, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Norian LA; Department of Nutrition Sciences, The University of Alabama at Birmingham, Birmingham, Alabama, USA lnorian@uab.edu.; The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Dec; Vol. 8 (2).

Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.

Autor: Kim MT; Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242; Carver College of Medicine, University of Iowa, Iowa City, IA 52242;, Richer MJ; Department of Microbiology, University of Iowa, Iowa City, IA 52242;, Gross BP; Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242;, Norian LA; Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242; Department of Urology, University of Iowa, Iowa City, IA 52242; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242; and., Badovinac VP; Department of Pathology, University of Iowa, Iowa City, IA 52242., Harty JT; Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242; Department of Microbiology, University of Iowa, Iowa City, IA 52242; Department of Pathology, University of Iowa, Iowa City, IA 52242 john-harty@uiowa.edu.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2015 Nov 01; Vol. 195 (9), pp. 4537-44. Date of Electronic Publication: 2015 Sep 25.

Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.

Autor: Makkouk A; Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, Iowa, 52242, USA., Joshi VB, Wongrakpanich A, Lemke CD, Gross BP, Salem AK, Weiner GJ

Publikováno v: The AAPS journal [AAPS J] 2015 Jan; Vol. 17 (1), pp. 184-93. Date of Electronic Publication: 2014 Oct 18.

Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Autor: Joshi VB; Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA., Geary SM, Gross BP, Wongrakpanich A, Norian LA, Salem AK

Publikováno v: Expert review of vaccines [Expert Rev Vaccines] 2014 Jan; Vol. 13 (1), pp. 9-15.